Technical Analysis for BCRX - BioCryst Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 4.21 2.68% 0.11
BCRX closed up 2.68 percent on Monday, August 21, 2017, on 80 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical BCRX trend table...

Date Alert Name Type % Chg
Aug 18 NR7 Range Contraction 2.68%
Aug 16 Stochastic Reached Oversold Other -1.17%
Aug 15 New Downtrend Bearish -3.66%
Aug 15 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -3.66%
Aug 15 180 Bearish Setup Bearish Swing Setup -3.66%

Older signals for BCRX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Profile
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops novel drugs that block key enzymes involved in the pathogenesis of diseases. The company integrates the disciplines of biology, crystallography, medicinal chemistry, and computer modeling to discover and develop small molecule pharmaceuticals through the structure-guided drug design process. Its product candidates include peramivir, an intravenous neuraminidase inhibitor, which is approved for seasonal influenza in Japan and Korea, as well as in Phase III clinical trials for acute influenza; ulodesine, an oral purine nucleoside phosphorylase inhibitor, which has completed Phase II clinical trials for the treatment of gout; and forodesine, an oral purine nucleoside phosphorylase inhibitor that is in Phase II clinical trials for oncology. The company's product candidates also comprise BCX4161, a Phase I oral serine protease inhibitor for kallikrein hereditary angioedema; and BCX4430, a preclinical, RNA dependent-RNA polymerase inhibitor for treating Filoviruses. It has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; and Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir. Biocryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Is BCRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 9.25
52 Week Low 3.75
Average Volume 883,708
200-Day Moving Average 6.1083
50-Day Moving Average 5.2962
20-Day Moving Average 4.681
10-Day Moving Average 4.345
Average True Range 0.2626
ADX 31.15
+DI 11.41
-DI: 28.53
Chandelier Exit (Long, 3 ATRs) 4.8822
Chandelier Exit (Short, 3 ATRs) 4.7378
Upper Bollinger Band 5.4563
Lower Bollinger Band 3.9057
Percent B (%b) 0.2
Bandwidth 0.331254
MACD Line -0.3391
MACD Signal Line -0.3053
MACD Histogram -0.0338